2-[(4-Methyl-5-propylfuran-2-yl)methyl]propanedioic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[(4-Methyl-5-propylfuran-2-yl)methyl]propanedioic acid
• 英文别名: 2-[(4-methyl-5-propylfuran-2-yl)methyl]propanedioic acid
• 化学式: C₁₂H₁₆O₅
• 分子量: 240.25
• InChiKey: IKQGPCMFSFOEOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• CMPF AS A BIOMARKER FOR DIABETES AND ASSOCIATED METHODS
  申请人：The Governing Council of the University of Toronto

  公开号：EP2897614A1

  公开（公告）日：2015-07-29
• SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS
  申请人：Robertson John L.

  公开号：US20170045455A1

  公开（公告）日：2017-02-16

  A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.
• US9726659B2
  申请人：——

  公开号：US9726659B2

  公开（公告）日：2017-08-08
• [EN] CMPF AS A BIOMARKER FOR DIABETES AND ASSOCIATED METHODS<br/>[FR] ACIDE CMPF UTILISÉ COMME BIOMARQUEUR POUR LE DIABÈTE ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV TORONTO

  公开号：WO2014043793A1

  公开（公告）日：2014-03-27

  Provided are methods for identifying or monitoring a subject having, or at risk of developing, impaired glucose homeostasis. Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is shown to be a biomarker for impaired glucose homeostasis and/or conditions characterized by β-cell dysfunction. Comparing a test level of CMPF in a subject to a control level identifies subjects having, or at risk of developing, impaired glucose homeostasis. Also provided are methods of causing impaired glucose homeostasis or β-cell dysfunction and methods of screening for compounds that affect the activity of β-cells. Also provided are methods for the treatment of β-cell dysfunction by reducing the physiological levels of CMPF in a subject as well as the use of a OAT modulator for the treatment of β-cell dysfunction.
• [EN] SYSTEM AND METHOD FOR MONITORING THE HEALTH OF DIALYSIS PATIENTS<br/>[FR] SYSTÈME ET PROCÉDÉ DE SURVEILLANCE DE L'ÉTAT DE SANTÉ DE PATIENTS SOUS DIALYSE
  申请人：ROBERTSON JOHN L

  公开号：WO2015164620A1

  公开（公告）日：2015-10-29

  A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.